FDA 2026 Rules: What Are the Limits for Using HSAT Devices for OSA Diagnosis?

FDA updated its guidance in 2026: as long as family physicians keep formal home sleep apnea testing (HSAT) or polysomnography (PSG) and your own clinical judgment at the center of the diagnostic process, while ensuring consumer-grade data and AI-assisted tools remain interpretable, supplementary, and non-diagnostic, they can generally practice within the safety margins defined by the FDA's current enforcement discretion framework.

This article explains why this shift happens, what that means in practice, and where the lines are drawn.

Home Sleep Apnea Test

Why Wearables are Gradually Preferred by Physicians in HSAT Workflows?

The shift from sleep lab to living room has accelerated. According to Signify Research's analysis of the sleep apnea market [1], HSAT and screening are scaling rapidly, driven by shifting clinical priorities around value-based care and advances in devices and telehealth.

• Major vendors are expanding their home-diagnostics funnels. Compumedics secures $15 million supply deal with Philips for the Australian pharmacy channel. ResMed acquired VirtuOx, a healthcare technology company that provides diagnostic tools and services.

  
  

• The sleep apnea market is vertically integrating. Vendors are consolidating their market positions by controlling the full pathway across diagnostics, treatment, and data services. Those lacking data capabilities or focusing solely on hardware face the risk of margin erosion.

  
  

• The U.S. reimbursement environment continues to support this acceleration, with Medicare and UnitedHealthcare reaffirming HSAT medical necessity as recently as 2025.

Driving this shift is a fundamental question: why are physicians moving away from traditional in-lab PSG toward HSAT?

PSG Vs HSAT: What’s the Difference?

Traditional PSG conducted in a sleep lab remains the diagnostic gold standard, capturing comprehensive data including electroencephalography (EEG), electromyography (EMG), airflow, and oxygen saturation. HSAT devices, while less comprehensive, are cleared medical devices specifically designed for home OSA screening and typically measure airflow, respiratory effort, and pulse oximeter readings. Here is a simple but direct comparison table of the two:

Feature	In-Lab Polysomnography (PSG)	Home Sleep Apnea Test (HSAT)
Setting	Sleep laboratory	Patient’s home
Supervision	Attended by medical staff	Unattended/Self-administered
Signals	Comprehensive (EEG, EOG, EMG, ECG, airflow, etc.)	Limited (Airflow, respiratory effort, oximetry)
Sleep Staging	Accurate (requires EEG)	Typically impossible (lacks EEG)
Diagnostic Index	Apnea-Hypopnea Index (AHI) based on sleep time	Respiratory Event Index (REI) based on recording time
Accuracy	Gold standard; most accurate	Consistency with PSG has risen to 89.7% (2026) [2]
Indications	Complicated patients (e.g., heart failure, stroke) or other sleep disorders	Uncomplicated adults with high pretest probability of OSA
Titration	Manual PAP titration by staff	Auto-titration (APAP) at home
Cost	High	35%-88% Lower[3]
Turnaround	Usually a month	2–5 business days[4]

According to this table, the shift is reasonable: By ensuring almost equivalent clinical outcomes for non-complex patients, HSAT significantly reduces healthcare costs and wait times while effectively eliminating the first-night effect, thereby substantially improving diagnostic accessibility and patient convenience.

FDA's Digital Health and CDS Guidance Framework in 2026

What Counts as an HSAT Device Under FDA Regulation?

On January 6, 2026, the FDA issued revised final guidance documents on both Clinical Decision Support (CDS) software and its General Wellness Policy for Low Risk Devices, superseding the 2022 and 2019 versions, respectively.[5]

Cleared HSAT devices are regulated Class II medical devices. They require 510(k) clearance and are explicitly indicated for the diagnosis of OSA. When a physician orders a home sleep apnea test using one of these devices, they are operating within a clinically and regulatorily defined pathway.

Wellness device / Consumer wearables — including pulse oximeters marketed for general wellness, smartwatches, and fitness rings — fall into a fundamentally different category. Under the revised General Wellness Guidance, the FDA clarified that it may consider certain products using non-invasive optical sensing to estimate physiologic parameters, including oxygen saturation, to be general wellness products when their outputs are intended solely for wellness uses and meet specific criteria.[6] This is an important clarification, but it comes with guardrails. According to legal analysis of the revised guidance, permissible wellness outputs must be non-invasive, intended solely for wellness, and must avoid clinical claims, thresholds, or prompts for medical management.[7]

The critical distinction for physicians: a "wellness" classification by the FDA means the device has not been validated for diagnostic purposes. It does not mean the data is clinically equivalent to data from a cleared device.

On the software side, the 2026 CDS Guidance reinforces that clinical decision support tools used by physicians can remain outside active FDA device regulation when they support healthcare professionals' decision-making using well-understood clinical data, generate recommendations for physician review and finalization, and do not analyze continuous physiologic signals or drive diagnosis directly.[8] The FDA specifically noted that software that processes multiple physiological signals from wearables to detect events such as heart attacks or narcolepsy episodes remains within medical device oversight — a standard equally applicable to sleep apnea detection.[5]

Safe Practices and Red Flags for Physicians Using Wearable Sleep Data

What You (as a Physician) Can Reasonably Do

• Use wearable data as a supportive context, not diagnostic input. If a patient presents with a prolonged pattern of low overnight oxygen saturation captured on a consumer oximeter, this can inform the clinical conversation and support the decision to order a formal home sleep apnea test. The wearable data serves as a prompt, not a conclusion.

  
  

• Keep any AI-assisted tools transparent and non-directive. The 2026 CDS Guidance places greater emphasis on transparency regarding data inputs and underlying logic, particularly for algorithmic or AI-driven tools.[8] If you use software to help interpret patient-reported wearable data, document the tool, its limitations, and the fact that your clinical judgment remained independent.

  
  

• Clearly document your independent clinical judgment. The FDA's enforcement discretion framework for CDS tools depends on the clinician being able to independently review the basis for any recommendation. Documentation that supports this — clinical notes, your own assessment, the formal HSAT or PSG result — protects both your patient and your practice.

Where the Risk Begins

• Do not equate consumer metrics with clinical measures. A consumer pulse oximeter's SpO2 reading and a medical-grade oximeter's SpO2 reading may look similar, but their validation standards are not equivalent. Wellness-category devices are not required to meet the clinical accuracy thresholds applied to cleared medical devices.

  
  

• Do not use wearable data as the sole or primary basis for prescribing CPAP or other OSA treatments. Prescribing therapy for OSA on the basis of consumer device data alone, without a formal HSAT or PSG, would bypass the diagnostic pathway that insurance payers, clinical guidelines, and the FDA's regulatory framework all require.

  
  

• Do not assume an FDA "wellness" classification means data is clinically validated. As legal analysts have noted, the enforcement discretion framework can be narrowed or withdrawn, and it does not confer clinical validity on the underlying measurements.[9]

A Physician Explaining OSA Diagnosis Result

What Happens If the Data Is Wrong?

If a physician relies on inaccurate wearable data to make a clinical decision, and a patient is harmed or receives inappropriate treatment, the physician carries the clinical and legal responsibility.

Consumer wearables are designed for general wellness monitoring under conditions that may differ substantially from a medically supervised sleep study. Motion artifact, ambient light interference, and skin tone can all affect pulse oximeter readings from optical sensors.

The FDA's enforcement discretion for general wellness devices does not transfer liability away from the prescribing clinician. It simply means the FDA is unlikely to take regulatory action against the device manufacturer. The standard of care for OSA diagnosis remains tied to validated, cleared HSAT devices or PSG, and courts and medical boards will apply that standard regardless of what a patient's smartwatch showed. This is why you should keep an eye on the reliability of wearable devices for HSAT.

How to Ensure the Security and Privacy of Patients’ Healthcare Information on Consumer Devices

If you are a family physician using consumer-grade health monitoring tools (such as wearables or apps) to collect patient data, you may be held legally liable if a data breach occurs. The following steps can help mitigate this risk:

1. Review and evaluate devices: regularly assess the data security of the devices and select those that comply with local regulations (e.g., HIPAA).

   
   

2. Provide full disclosure of risks to patients: before recommending or using consumer-grade tools, physicians should fulfill their duty of disclosure in writing to ensure patients understand the data workflow and potential risks. This includes:

• Clarify device classification: Inform patients that the device is "consumer-grade" rather than "medical-grade," and that its standards for data accuracy and security may differ from professional hospital equipment.

  
  

• Disclose data flow: Clearly state that data will be stored on third-party clouds (e.g., manufacturer servers) rather than exclusively within the clinic's system.

  
  

• Obtain informed consent: Require patients to sign a specific informed consent form that includes liability waivers for uncontrollable risks, such as data breaches or hacking incidents occurring on third-party platforms.

  
  

• Offer alternatives: Inform patients that they may opt for traditional clinical monitoring if they have privacy concerns, ensuring their decision is entirely voluntary.

3. Ensure a BAA (Business Associate Agreement) is in Place: Confirm that your institution has signed a BAA with the device manufacturer; independent practitioners must also sign these agreements individually.

   
   

Why O2ringS is the Best FDA-Cleared Device for HSAT Seamless Workflow Integration

The choice of device matters from a compliance and communication standpoint.

Viatom O2Ring Series Ring Oximeter

Viatom O2Ring series pulse oximeter is positioned clearly within the wellness monitoring space. Viatom states explicitly that its products are designed to allow physicians to easily monitor and record oxygen saturation levels, carrying FDA and CE approvals. The O2Ring S upgrades sampling frequency from 150 Hz to 200 Hz with extended battery life, enabling meaningful overnight trend data. The companion app allows Bluetooth synchronization for patient-shared data review.

Critically for physician protection, Viatom's product labeling does not position these devices as OSA diagnostic tools. That clarity in intended use is precisely what the FDA's 2026 General Wellness Guidance describes as appropriate for wellness-category devices—outputs that are informational, non-diagnostic, and free from clinical threshold claims.

Conclusion

FDA's 2026 guidance gives family physicians something they have long needed: clearer direction on where consumer wearables fit within an HSAT workflow. That clarity, however, cuts both ways. The same rules that open the door for using smart devices also define the limits of how far they can go. When every tool in your workflow has a defined role and a clear intended use, choosing these HSAT devices becomes a defensible, patient-centered decision.

References

1. Sean Davis, "Competitive Evolution in the Sleep Apnea Market: Data, Diversification, and Digital Integration," Signify Research, November 6, 2025. https://www.signifyresearch.net/insights/competitive-evolution-in-the-sleep-apnea-market-data-diversification-and-digital-integration/

2. Cushman, P., Radtke, A., Kang, J., Burch, A., Tchopev, Z. N., Brock, M. S., & Scheuller, H. S. (2026). Modified scoring criteria to improve the accuracy of the home sleep apnea test. Sleep & breathing = Schlaf & Atmung, 30(1), 52. https://doi.org/10.1007/s11325-026-03598-y 

3. Ghegan, M. D., Angelos, P. C., Stonebraker, A. C., & Gillespie, M. B. (2006). Laboratory versus portable sleep studies: a meta-analysis. The Laryngoscope, 116(6), 859–864. https://doi.org/10.1097/01.mlg.0000214866.32050.2e 

4. Admin-Bw. “Home Sleep Test Vs. In-Lab Sleep Study: Accuracy, Indications, and Cost.” BreatheWorks, 12 Dec. 2025, https://breatheworks.com/home-sleep-test-vs-sleep-study/ 

5. Covington & Burling LLP, "5 Key Takeaways from FDA's Revised Clinical Decision Support (CDS) Software Guidance," January 2026. https://www.cov.com/en/news-and-insights/insights/2026/01/5-key-takeaways-from-fdas-revised-clinical-decision-support-cds-software-guidance

6. Ropes & Gray LLP, "FDA Adapts with the Times on Digital Health," January 2026. https://www.ropesgray.com/en/insights/alerts/2026/01/fda-adapts-with-the-times-on-digital-health-updated-guidances-on-general-wellness-products

7. ArentFox Schiff, "FDA Issues Updated Guidance on Low-Risk General Wellness Devices and Clinical Decision Support Software," February 2026. https://www.afslaw.com/perspectives/alerts/fda-issues-updated-guidance-low-risk-general-wellness-devices-and-clinical

8. Faegre Drinker, "Key Updates in FDA's 2026 General Wellness and Clinical Decision Support Software Guidance," January 2026. https://www.faegredrinker.com/en/insights/publications/2026/1/key-updates-in-fdas-2026-general-wellness-and-clinical-decision-support-software-guidance

9. Gardner Law, "FDA's 2026 CDS and General Wellness Guidance Updates," January 2026. https://gardner.law/news/fda-2026-cds-wellness-guidance-updates